Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative
Clinical trial NCT03765775 · UNKNOWN
Trial details
- NCT number
- NCT03765775
- Sponsor
- First Hospital of Shijiazhuang City
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-20
- Primary completion
- 2019-12-31
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.